Elan Corporation, plc ELN today announced that it has commenced a Phase
2, placebo-controlled, safety and efficacy study of oral ELND005 as an
adjunctive maintenance treatment in patients with Bipolar I Disorder (BPD 1)
to delay the time to occurrence of mood episodes. The first patient has been
dosed in the study.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in